Apimeds Pharmaceuticals US, Inc. (APUS): Total Liabilities
$10.84M
As of 2025-12-31
$21.18M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.84M | +690.3% | 2026-05-04, Balance as of period end |
| 2024-12-31 | $1.37M | +251.4% | 2026-05-04, Balance as of period end |
| 2023-12-31 | $390.2K | n/a | 2025-04-15, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | 2025-12-31 | $10.84M | +690.3% |
| Cypherpunk Technologies Inc. (CYPH) | 2025-12-31 | $9.68M | -31.3% |
| Transcode Therapeutics, Inc. (RNAZ) | 2025-12-31 | $10.52M | +12.9% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $23.85M | -11.7% |
| Climb Bio, Inc. (CLYM) | 2025-12-31 | $7.27M | +37.0% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $57.38M | -11.4% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $194.09M | +20.1% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 2025-12-31 | $20.69M | +53.8% |
| Eledon Pharmaceuticals, Inc. (ELDN) | 2025-12-31 | $32.23M | -45.6% |
Compare APUS, CYPH, RNAZ, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗